Atlas Trials

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Clinical trial NCT06498921 · COMPLETED

Trial details

NCT number
NCT06498921
Sponsor
Bayer
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Hormone-sensitive Prostate Cancer
Start date
2024-07-15
Primary completion
2024-09-15
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.